Prostamax

Overview

Prostamax is a short synthetic tetrapeptide with the sequence Lys-Glu-Asp-Pro (one-letter KEDP). It belongs to the family of "short peptide bioregulators" associated with the Russian gerontologist Vladimir Khavinson and the Saint Petersburg school, and it is marketed commercially as a "prostate bioregulator." Its identity and chemistry are well established in PubChem (CID 9848296): formula C20H33N5O9, molecular weight ~487.5 g/mol.

The important thing to understand about Prostamax is a gap between its marketed purpose and its actual published evidence. The peer-reviewed literature on the synthetic KEDP peptide is a small, older, mostly Russian- and Georgian-journal body of in-vitro work on chromatin de-condensation and gerontology — carried out in cultured human blood lymphocytes (including cells from elderly donors) and in rat organotypic tissue cultures. It is not a set of prostate clinical trials. No human prostate efficacy trials of the synthetic peptide were found, there is no independent (non-originating- institute) replication, and no Western randomized controlled trial.

The prostate clinical evidence commonly cited in marketing belongs to the separate bovine prostate extracts Prostatilen and Vitaprost, which are different products from the synthetic KEDP tetrapeptide. Prostamax has no FDA or EMA approval for any indication and, in Western markets, is supplied strictly as a research reagent ("not for human consumption").

Prostamax sits alongside other Khavinson-class bioregulators such as Epitalon and Thymalin — compounds where bold "bioregulation" claims rest on a narrow, largely single-school, mostly-preclinical evidence base.

Chemistry and structure

Prostamax is a linear tetrapeptide (four amino acids) with the sequence:

Lys-Glu-Asp-Pro (one-letter: KEDP; H-Lys-Glu-Asp-Pro-OH)

The name, formula, weight, and IUPAC identity consistent with Lys-Glu-Asp-Pro are confirmed in PubChem (CID 9848296). The CAS number (473578-47-1) is listed only within the PubChem synonym list and was not independently verified against the CAS Registry itself, so it is reported here as such rather than as a confirmed registry value.

Mechanism of action

The mechanisms attributed to Prostamax are best read as hypotheses or as in-vitro observations, not as established physiological actions in humans. None has a characterized receptor or a validated molecular target; the DNA/chromatin-binding idea is hypothesized and has not been independently confirmed for KEDP.

• Proposed epigenetic "bioregulation" (chromatin de-condensation). The peptide is hypothesized to enter the nucleus, interact with chromatin/DNA, and de-condense (deheterochromatinize) previously silenced heterochromatin, reactivating gene expression (e.g. ribosomal genes) in aged cells. [In vitro] — cultured human peripheral blood lymphocytes, including cells from elderly/"senile" donors, assessed by heterochromatin/ chromatin-activation morphometry in situ (PMID 23221144, PMID 15612551, PMID 15085253).
• Tissue-specific effects of synthetic short peptides, reported to differ between young and old animals. [In vitro] — rat organotypic tissue culture, young vs old (PMID 17152728).
• Claimed tissue-specific stimulation of prostate cell/gene activity, with zinc-binding invoked in marketing as a mechanistic rationale. [Hypothesis] — this is a marketing/secondary-source claim; it is not supported by any located primary prostate study of KEDP (peptibase.dev summary (opens in a new tab)).

Research and evidence

The published evidence on the synthetic KEDP peptide is old, small, largely in-vitro, and concentrated in the originating research school. The studies that exist measure chromatin and cellular-aging endpoints, not prostate clinical outcomes.

Human evidence

There are no well-established human clinical trials of the synthetic KEDP peptide. No published human clinical efficacy trials of Prostamax were found. The peer-reviewed "prostamax"/KEDP literature is on chromatin and gerontology endpoints in cultured human blood lymphocytes and rat organotypic tissue — not prostate clinical outcomes. Studies using lymphocytes from elderly donors are ex vivo cell-culture work, not in-vivo human efficacy. The prostate clinical evidence commonly cited in marketing belongs to the separate bovine prostate extracts Prostatilen/Vitaprost, not to synthetic KEDP. No independent (non-originating-institute) replication and no Western RCT were located.

Status and regulation

Prostamax has no FDA or EMA approval for any indication and is not an authorised medicine in the US or EU. In Western markets it is sold only as a research reagent ("not for human consumption").

Secondary sources describe it as marketed in Russia within Khavinson's peptide-bioregulator product line, but a specific Russian pharmaceutical registration for the synthetic KEDP tetrapeptide was not verified in the primary or regulatory sources found — and that Russian-approval framing may conflate it with the bovine extracts Prostatilen/Vitaprost. Regulatory classification varies by jurisdiction. This is not medical or legal advice; verify locally (as of 2026-07).

Safety

• No human safety data. No human pharmacokinetics, bioavailability, half-life, or safety/toxicology data for the synthetic peptide were found.
• No standardized dosing. No validated dosing exists; any dosing figures in circulation are vendor/protocol material, not from controlled human trials.
• Unverified products. Material sold as "Prostamax" is a research reagent; its identity, purity, and contaminant profile cannot be assumed to be controlled.
• Injectable-peptide risks. Where handled as an injectable in unregulated settings, the usual risks of non-sterile injectable products apply.

Legal status

Prostamax is best described by its regulatory classification: in the US and EU it is an unapproved compound supplied as a research reagent, not a medicine authorised for human use. The absence of a specific ban is not affirmative permission — a compound becomes an unauthorised medicine the moment it is intended for human use. A specific national supplement or pharmaceutical registration for the synthetic KEDP tetrapeptide was not located in a primary source.

WADA status is not established for Prostamax: no source found asserts a prohibition or a class code, and non-approval must not be read as implying any particular WADA class. Sport-eligibility is a separate axis from legality — athletes should consult current WADA guidance rather than assume permission.

This is not legal advice, and regulatory status varies by jurisdiction — check your local rules (as of 2026-07).

How it compares

Prostamax is one of several Khavinson-class short peptide "bioregulators" where the marketed promise runs ahead of the evidence:

• Epitalon — a synthetic pineal-associated tetrapeptide (Ala-Glu-Asp-Gly) promoted for longevity. Like Prostamax, its claims rest largely on older, single-school, mostly-preclinical work with limited independent replication.
• Thymalin — a bovine-thymus peptide extract from the same research school, registered in Russia as an immunomodulator but not FDA/EMA-approved. It illustrates the recurring pattern of bold claims with narrow, largely non-independent evidence.

The honest comparison: all three share a narrow, largely single-group, mostly-preclinical evidence base, and none of Prostamax's marketed prostate purpose is backed by a located primary human study.

Common misconceptions

• "Prostamax is a proven prostate treatment." It is not. No human prostate efficacy trial of the synthetic KEDP peptide was found; the located literature is in-vitro chromatin/ gerontology work, and the prostate clinical data usually cited belongs to the separate bovine extracts Prostatilen/Vitaprost.
• "The clinical studies on prostate extracts prove Prostamax works." They do not concern the synthetic peptide. Prostatilen/Vitaprost are different products (bovine prostate extracts), and their data cannot be transferred to KEDP.
• "It's approved in Russia, so it's an established medicine." A specific Russian registration for the synthetic KEDP tetrapeptide was not verified in primary sources; the Russian-approval framing comes from secondary sources and may conflate it with the bovine extracts. It is not FDA- or EMA-approved.
• "There's a confirmed mechanism." There is no characterized receptor or validated target. The chromatin/DNA-binding idea is a hypothesis and has not been independently confirmed for KEDP.
• "No specific ban means it's legal to take." No. Absence of a ban is not permission, and a compound becomes an unauthorised medicine the moment it is intended for human use.

Russian research

Much of the primary literature on prostamax comes from a single interlinked Russian school — Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and its Georgian collaborators (Lezhava, Dzhokhadze, Monaselidze) in Tbilisi. It is surfaced here for completeness and framed honestly: the body of evidence is small, single-institute, largely older, and has no independent replication outside the originating group. Being studied is not being proven.

Across the indexed primary literature, only five studies actually examine prostamax's effects, and four of the five are in-vitro/ex-vivo work on aging chromatin and cellular endpoints in cultured human lymphocytes — not on the prostate:

• [In vitro] Deheterochromatinization of chromatin in old age induced by the oligopeptide bioregulator prostamax (Lys-Glu-Asp-Pro) in cultured human lymphocytes (PMID 23221144, Georgian Med News 2012).
• [In vitro] Influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ — chromatin/morphometric endpoints in lymphocyte culture (PMID 15612551, Biofizika 2004).
• [In vitro] Human lymphocyte-culture study in which prostamax is named alongside Epithalon and Livagen as producing decondensation of chromosome-1 pericentromeric chromatin; the abstract reports this qualitatively and does not isolate a quantified prostamax-only effect (PMID 15085253, Bull Exp Biol Med 2004 — one of the more robustly verifiable, Springer-translated citations).
• [In vitro] Microcalorimetric study of human blood-lymphocyte culture in the presence of copper, cadmium and prostamax; the abstract characterizes the metal ions and does not clearly isolate a prostamax-specific result (PMID 19359734, Georgian Med News 2009 — Georgian-journal source with limited independent full-text availability).
• [Animal] The only study touching prostate tissue is a rat organotypic explant (ex-vivo tissue-culture) assay of tissue-specific peptide effects — not a whole-animal or human prostate-disease study (PMID 17152728, Adv Gerontol 2006 — Springer-translated and among the more verifiable citations).

A sixth PubMed record (Khavinson VK, Kormilets DY, Mar'yanovich AT, "Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan," Bull Exp Biol Med 2017, DOI 10.1007/s10517-017-3876-x, PMID 28948547) is real, but prostamax appears only in the record's indexed substances, not in the abstract, which is a rodent sequence-motif bioinformatics analysis; it does not study prostamax's effects and is not evidence of efficacy. Several marketed claims could not be verified against any primary source: the "anti-inflammatory/tissue-protective effects in chronic prostatitis models" claim appears only in vendor/secondary marketing copy and no primary prostatitis-model study was located; the "zinc-binding / tissue-specific stimulation of prostate gene activity" mechanism is a marketing hypothesis [Hypothesis] with no primary study characterizing a receptor, molecular target, or zinc-binding mechanism; and whether prostamax was among the peptides in the Drosophila antioxidant study (Mylnikov et al., Ecological Genetics 2008, DOI 10.17816/ecogen6134-42) is not confirmed — the resolving abstract names only Vilon and Epithalon, so it is not cited as prostamax evidence.

Quality, plainly: the located evidence is small, single-group, descriptive (morphometry, microcalorimetry, cytogenetics), clustered around 2004–2012, and under-replicated — zero independent replication, zero Western studies, zero randomized controlled trials, and no human clinical efficacy trial of the synthetic KEDP tetrapeptide. On regulation, no source located asserts a specific Russian pharmaceutical registration number for the synthetic KEDP "Prostamax"; Russian-language sources describing prostatic-peptide preparations "registered/used in Russia" appear to conflate the synthetic peptide with the bovine-derived prostate extracts (the Prostatilen/Vitaprost/Libidon cytomedin line), which are what actually carry Russian registrations — so "registered medicine in Russia" could not be verified for the synthetic peptide. There is no FDA or EMA approval for any indication, and Western material sold as "Prostamax" is labelled for laboratory/in-vitro use only. In short: chemically well-defined, but evidentially unproven — and any Russian regulatory status is a regulatory-adjacent fact, not proof of efficacy.